In vivo imaging and quantification of central norepinephrine transporters (NET) by [11C]MRB positron emission tomography (PET)/magnetic resonance imaging (MRI) in adult patients with attention-deficit/hyperactivity disorder (ADHD) and emotional dysregulation (ED) - ADHD-EMOTIO

niversität Leipzig0 个研究点目标入组 40 人开始时间: 2024年1月19日最近更新: 2024年8月19日

适应症

试验速览

暂无简介。

•Signed informed consent for study participation,
•Confirmed primary diagnosis of adult ADHD according to DSM-5,
•Medication naïve or with previous use of psychostimulants, antidepressants, or atomoxetine after a 4-week washout period of the respective medication,
•Ability to perform a computerized neurobiological test battery,
•Sufficient understanding of the German language,
•Consent according to §7 Abs.2 Nr.15 of the GCP regulation about the passing on of the pseudonymized data in the context of the documentation and notification duties according to §12 and §13 GCP regulation.

•Lack of capacity to consent,
•Acute suicidality,
•Current depressive disorder, single or recurrent episode,
•Emotionally unstable personality disorder, borderline type,
•Schizophrenia spectrum and other psychotic disorders,
•Bipolar and related disorders,
•Alcohol and/or drug dependence as a primary diagnosis and/or a positive urine drug screen,
•Mental disorders with a known physiological etiology,
•Intelligence deficits,
•Treatment with a neurostimulation procedure within the past 6 months,
•Contraindications to PET or MRI scan,
•Severe somatic or neurological comorbidity or unstable clinical condition within the past 12 months that affects cognitive performance,
•Caregiving and/or institutionalization,
•Pregnancy or positive urine pregnancy test, lactation.
•Lack of compliance

发起方

niversität Leipzig